securities fraud

Pomerantz Law Firm investigates $CFLT over undisclosed AI customer spending reduction that caused stock to crash 32.86% on July 31, 2025.

Boston Scientific faces class action lawsuit alleging material misstatements about electrophysiology growth. Stock fell 17.6% after disclosing slower market growth and competitive pressures.

Goldman Sachs sued as lead underwriter for allegedly failing to disclose 39% surge in Navan's marketing costs before October 2025 IPO, resulting in 63% stock collapse.

Pomerantz LLP filed securities fraud class action against Nektar Therapeutics, alleging false statements about clinical trial enrollment procedures led to trial failure and stock decline.

$LAKE faces class action suit alleging executives misrepresented acquisition integration and hid operational problems, leading to 39% stock crash.

Pomerantz LLP sues Inovio Pharmaceuticals for alleged securities fraud over FDA approval misstatements. Stock fell 3.1% and 24.45% following manufacturing delays and accelerated approval rejection.

Pomerantz Law Firm files class action against Enphase Energy over alleged misstatements regarding inventory management and federal solar tax credit impacts. Stock fell 15.15% after weak Q3 guidance.

Schall Law Firm seeks $PSIX investors for class action over alleged false statements on data center business and manufacturing costs. Deadline: May 19, 2026.

Navan investors face April 2026 deadline to join class action over allegedly misleading IPO disclosures. Stock has fallen 63% after undisclosed 39% expense increase announcement.

Schall Law Firm seeks class action participants against Gartner ($IT) for alleged securities fraud involving false statements on seasonality risks and tariff impacts. Deadline May 18, 2026.

Schall Law Firm launches securities fraud class action against $GEMI, alleging misleading statements about crypto platform and expansion plans since September 2025 IPO.

Zynex faces securities class action lawsuit following bankruptcy, $85M fraud settlement, and delisting after alleged systematic overbilling scheme.

ODDITY Tech ($ODD) faces securities fraud lawsuit after 49% stock plunge over alleged non-disclosure of advertising algorithm changes that spiked customer acquisition costs.

Class action lawsuit filed against $LU alleging securities fraud, false statements, and weak internal controls from April 2023 through January 2025.

Class action filed against $SNOW alleging securities fraud over failure to disclose product efficiency impacts on consumption, revenues during June 2023-February 2024 period.

BlackRock TCP Capital Corp. (TCPC) faces class action lawsuit alleging securities fraud over materially false portfolio valuations and overstated net asset value between November 2024 and January 2026.

Mereo BioPharma faces class action lawsuit alleging misrepresentations regarding failed Phase 3 clinical trials, with lead plaintiff deadline April 6, 2026.

Class action lawsuit filed against $COPT alleging executives misrepresented relacorilant clinical trial strength and FDA approval prospects, harming investors.

Class action lawsuit filed against $NKTX alleging executives made false statements about REZOLVE-AA trial integrity. Investors urged to join by May 5, 2026 deadline.

Class action filed against Driven Brands alleging false financial statements, weak controls, and unreconciled cash from 2023, affecting fiscal years 2023-2024.